On January 20, the Federal Trade Commission approved a 14-day suspension of its administrative case against the nation’s largest pharmacy benefit managers, including CVS Health’s Caremark unit. The stay postpones all discovery, filing deadlines and the evidentiary hearing—now scheduled for July 1—while regulators explore a potential settlement. The original complaint, filed in September 2024, accuses PBMs of leveraging rebate structures to drive up list prices on insulin. The FTC’s interim report last month highlighted markups of several hundred percent on specialty drugs, intensifying scrutiny on CVS Caremark’s pricing practices and signaling that negotiated resolution talks are underway.

On January 23, CVS Health initiated its major winter storm preparedness across more than 9,000 retail pharmacies and its pharmacy benefit manager business. CVS Pharmacy has dispatched text, email and phone alerts to encourage early prescription refills, deployed extra stocks of water, batteries and first-aid supplies, and implemented a one-time emergency refill policy for a 10-day supply through CVS Caremark in states under emergency declarations. Walk-in clinic and Specialty teams are coordinating alternate delivery for high-risk patients, while Aetna clinical response units have expanded outreach to Medicare, Medicaid and commercial members in affected regions. Stores complying with evacuation orders will route phone lines to open locations and reopen within 24 hours whenever safely possible.

At a January 22 announcement, CVS Health underscored its progress in reducing friction and cost across its integrated model. In 2024 the company generated $474 billion in economic contributions and directly employed over 300,000 Americans, supporting an additional one million jobs through its supply chain. As of September 30, 2025, CVS operated 9,000 community pharmacies, 1,000 medical clinics and served 87 million pharmacy benefit members. Initiatives highlighted include streamlined prior authorizations, expanded no-cost preventive care, free virtual visits and targeted efforts to lower prescription drug expenses—measures designed to drive down insurance premiums and improve outcomes for the 185 million consumers served annually.